S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Twitter executive responsible for content safety resigns after Elon Musk criticism
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Twitter executive responsible for content safety resigns after Elon Musk criticism
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Twitter executive responsible for content safety resigns after Elon Musk criticism
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Twitter executive responsible for content safety resigns after Elon Musk criticism
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
NASDAQ:GLSI

Greenwich LifeSciences (GLSI) Stock Forecast, Price & News

$10.97
+0.30 (+2.81%)
(As of 06/2/2023 ET)
Compare
Today's Range
$10.31
$11.04
50-Day Range
$10.35
$14.11
52-Week Range
$6.82
$21.50
Volume
47,710 shs
Average Volume
17,001 shs
Market Capitalization
$140.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$38.00

Greenwich LifeSciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
246.4% Upside
$38.00 Price Target
Short Interest
Healthy
6.76% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$126,002 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.93 out of 5 stars

Medical Sector

599th out of 983 stocks

Pharmaceutical Preparations Industry

298th out of 486 stocks


GLSI stock logo

About Greenwich LifeSciences (NASDAQ:GLSI) Stock

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Receive GLSI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Greenwich LifeSciences and its competitors with MarketBeat's FREE daily newsletter.

GLSI Stock News Headlines

How A.I. Could Make Most 21st Century Diseases EXTINCT
On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...
East Greenwich High School
Greenwich Junior-Senior High School
WARNING to all American Investors
China's sneaky plan could wipe out your retirement - in a single morning. Learn how to protect yourself here>>>
See More Headlines

GLSI Price History

GLSI Company Calendar

Today
6/03/2023
Next Earnings (Estimated)
8/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GLSI
Fax
N/A
Employees
3
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$38.00
High Stock Price Forecast
$38.00
Low Stock Price Forecast
$38.00
Forecasted Upside/Downside
+246.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-7,820,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.91 per share

Miscellaneous

Free Float
6,149,000
Market Cap
$140.96 million
Optionable
Not Optionable
Beta
0.89

Key Executives

  • Mr. Snehal S. PatelMr. Snehal S. Patel (Age 60)
    CEO, CFO & Director
    Comp: $925k
  • Mr. Eric Rothe (Age 48)
    Founder & Independent Director
  • Dr. Frank Joseph Daugherty M.D.Dr. Frank Joseph Daugherty M.D. (Age 73)
    Chief Medical Officer & Director
  • Dr. Jaye L. Thompson Ph.D. (Age 57)
    VP of Clinical & Regulatory Affairs
  • Dr. Christine T. Fischette Ph.D. (Age 72)
    VP of Bus. Devel.













GLSI Stock - Frequently Asked Questions

Should I buy or sell Greenwich LifeSciences stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Greenwich LifeSciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GLSI shares.
View GLSI analyst ratings
or view top-rated stocks.

What is Greenwich LifeSciences' stock price forecast for 2023?

1 Wall Street research analysts have issued 12 month price targets for Greenwich LifeSciences' shares. Their GLSI share price forecasts range from $38.00 to $38.00. On average, they anticipate the company's stock price to reach $38.00 in the next twelve months. This suggests a possible upside of 246.4% from the stock's current price.
View analysts price targets for GLSI
or view top-rated stocks among Wall Street analysts.

How have GLSI shares performed in 2023?

Greenwich LifeSciences' stock was trading at $15.20 at the start of the year. Since then, GLSI shares have decreased by 27.8% and is now trading at $10.97.
View the best growth stocks for 2023 here
.

When is Greenwich LifeSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our GLSI earnings forecast
.

When did Greenwich LifeSciences IPO?

(GLSI) raised $7 million in an initial public offering on Friday, September 25th 2020. The company issued 1,300,000 shares at $5.75 per share. Aegis Capital acted as the underwriter for the IPO.

What is Greenwich LifeSciences' stock symbol?

Greenwich LifeSciences trades on the NASDAQ under the ticker symbol "GLSI."

Who are Greenwich LifeSciences' major shareholders?

Greenwich LifeSciences' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (0.44%), Renaissance Technologies LLC (0.40%), Susquehanna International Group LLP (0.29%), HRT Financial LP (0.14%), Jane Street Group LLC (0.14%) and Citigroup Inc. (0.10%). Insiders that own company stock include David Mcwilliams, Frank Joseph Daugherty, Jaye Thompson, Kenneth Hallock and Snehal Patel.
View institutional ownership trends
.

How do I buy shares of Greenwich LifeSciences?

Shares of GLSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Greenwich LifeSciences' stock price today?

One share of GLSI stock can currently be purchased for approximately $10.97.

How much money does Greenwich LifeSciences make?

Greenwich LifeSciences (NASDAQ:GLSI) has a market capitalization of $140.96 million.

How can I contact Greenwich LifeSciences?

The official website for the company is www.greenwichlifesciences.com. The company can be reached via phone at 832-819-3232 or via email at info@greenwichlifesciences.com.

This page (NASDAQ:GLSI) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -